Anavex Life Sciences Corp. (NASDAQ:AVXL) Stock Holdings Raised by Barclays PLC

Barclays PLC raised its position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 70.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,179 shares of the biotechnology company's stock after purchasing an additional 64,101 shares during the quarter. Barclays PLC owned 0.18% of Anavex Life Sciences worth $882,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orion Capital Management LLC grew its stake in Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after buying an additional 10,000 shares during the period. Atria Investments Inc purchased a new stake in Anavex Life Sciences during the 3rd quarter worth $76,000. BNP Paribas Financial Markets boosted its position in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock worth $86,000 after purchasing an additional 7,421 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Anavex Life Sciences by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company's stock valued at $93,000 after purchasing an additional 6,366 shares during the period. Finally, Erste Asset Management GmbH purchased a new position in Anavex Life Sciences in the third quarter valued at about $102,000. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Trading Up 8.2 %

NASDAQ:AVXL traded up $0.86 on Wednesday, reaching $11.33. The stock had a trading volume of 1,588,811 shares, compared to its average volume of 2,395,162. The company has a 50-day moving average of $9.61 and a 200 day moving average of $7.10. The stock has a market cap of $960.97 million, a P/E ratio of -22.66 and a beta of 0.70. Anavex Life Sciences Corp. has a 12-month low of $3.25 and a 12-month high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, equities analysts predict that Anavex Life Sciences Corp. will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AVXL. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday. HC Wainwright upped their price target on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, December 26th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.